Company intelligence / Profile preview

LAM Therapeutics

Guilford, Connecticut, United Stateslamtherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

LAM advanced three drugs into clinical trials. LAM‑001 showed excellent safety/pharmacokinetics in Phase I for lymphangioleiomyomatosis and was moving into further trials. LAM‑002 demonstrated broad anti-cancer activity as a first-in-class PIKfyve kinase inhibitor for B-cell non-Hodgkin lymphoma. LAM‑003, an immune-modulating small molecule for hematological cancers/AML, completed Phase I and was being tested further.

Therapeutic areas: OncologyRare Diseases
Modalities: Small moleculesKinase inhibitorsmTOR inhibitorsImmune modulators
Industry: Biotech

Drug pipeline

3 assets

LAM-001

Phase 1

Indications: Lymphangioleiomyomatosis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on LAM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAM Therapeutics.

Explore the full profile